Biohaven Ltd.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies targeting unmet needs in neuroscience, immunology, and oncology. Founded in 2013 and headquartered in New Haven, Connecticut, the company operates globally with a portfolio spanning multiple proprietary drug development platforms, including Kv7 ion channel modulation, extracellular protein degradation via MoDE and TRAP technologies, TRPM3 antagonism, TYK2/JAK1 inhibition, glutamate modulation, myostatin inhibition, and antibody-drug conjugates. Its lead product candidate, Vyglxia (troriluzole), a tripeptide prodrug of riluzole, targets spinocerebellar ataxias (SCA) and received a Complete Response Letter from the U.S. FDA in November 2025 following submission of its New Drug Application, prompting Biohaven to pursue discussions with the agency and implement portfolio prioritization and cost-optimization measures slashing R&D expenses by approximately 60%. Core pipeline assets include taldefgrobep, a myostatin inhibitor in development for spinal muscular atrophy and obesity; BHV-7000, a selective Kv7.2/7.3 activator for epilepsy, major depressive disorder, and bipolar depression; BHV-2100, a TRPM3 antagonist for pain disorders; BHV-8000, a brain-penetrant TYK2/JAK1 inhibitor for Parkinson's disease, Alzheimer's disease, multiple sclerosis, and prevention of amyloid-related imaging abnormalities; BHV-1300 and BHV-1310, IgG degraders for rheumatoid arthritis, Graves' disease, and myasthenia gravis; BHV-1400, a Gd-IgA1 degrader for IgA nephropathy; BHV-1600, a β1AR autoantibody degrader for peripartum cardiomyopathy; and oncology candidates such as BHV-1510 (Trop2 ADC), BHV-1530 (FGFR3 ADC), and BHV-1500 (CD30 ADC), alongside undisclosed targets from collaborations with Merus and GeneQuantum. Recent developments encompass a non-dilutive financing agreement with Oberland Capital Management in April 2025 providing up to $600 million in senior secured notes to support pipeline advancement and potential launches; an upsized public offering of common shares in November 2025 generating approximately $200 million in gross proceeds; first-in-human dosing with BHV-1400 demonstrating rapid Gd-IgA1 lowering in IgA nephropathy; and ongoing advancement of preclinical antibody-drug conjugates. Biohaven, which emerged from the 2022 spin-off and divestiture of its migraine portfolio (including Nurtec ODT and Zavzpret) to Pfizer, targets patients with rare genetic disorders, neurodegenerative conditions, autoimmune diseases, chronic pain, metabolic disorders, and cancers across the United States and international markets.
Company News
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
Biohaven Rebounds With FDA Review Date for Rare Disease Drug
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
BlackRock Inc. Invests $196.57 Million in Biohaven Ltd. $BHVN
Why Biohaven Stock Was Rocking the Market This Week
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
Why Is Biohaven Stock Soaring Wednesday?
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy